Takrolimusa Baðlý Aldosteron Rezistansý Olgu Sunumu

Amaç: Takrolimus ile daha sýk görülmekle birlikte kalsinörün inhibitörlerinin hiporeninemik hipoaldosteronizm benzeri tablo geliþtirerek hiponatremi ve hiperkalemi gibi elektrolit bozukluklarýna yol açabildiði bilinmektedir.
Olgu: Yazýmýzda 32 yaþýnda renal transplantasyon yapýlan ve takibinin 149. gününde hiponatremi ve hiperkalemi ile baþvuran, tetkiklerinde normal anyon açýklý metabolik asidoz ve renal tübüler disfonksiyon saptanan, diðer nedenler dýþlandýktan sonra takrolimusa baðlý elektrolit bozukluðu düþünülen vaka verilmektedir. Hastada takrolimusun everolimusa deðiþimi ile yanýt alýnamamýþ ve aldosteron rezistansýna baðlý tübüler disfonksiyon düþünülerek fludrokortizon baþlanmýþ, elektrolit bozukluklarý hýzla düzelmiþtir.
Sonuç: Böbrek nakli hastalarýnda takrolimusa baðlý hiponatremi ve/veya hiperkalemi saptandýðýnda fludrokortizon tedavisi akla gelmelidir.

Aldosterone Resistance Due to Tacrolimus: A Case Report

Although more common with tacrolimus, it is known that calcineurin inhibitors may induce the development of electrolyte disorders such as hyponatremia and hyperkalemia by causing a hyporeninemic hypoaldosteronism-like syndrome. We present a 32-year-old female renal transplant patient who admitted to clinic with hyponatremia and hyperkalemia. Normal anion gap metabolic acidosis and renal tubular dysfunction were detected and after other reasons were excluded, it was considered as electrolyte disorder due to tacrolimus. No response was detected after tacrolimus conversion to everolimus and considering tubular dysfunction due to aldosterone resistance, we initiated fludrocortisone therapy and electrolyte disorders rapidly improved. Fludrocortisone therapy should be considered when hyponatremia and/or hyperkalemia due to tacrolimus are detected in renal transplant patients.